Table 6.

Summary of bortezomib phase III trials conducted in the upfront setting in patients not eligible for transplantation

^aStatistically significant difference between arms.

^bMedian OS not reached in either arm.

^cMajor AEs/AEs that differ between arms.

Abbreviations: AE, adverse event; CR, complete response; GI, gastrointestinal; MP, melphalan plus prednisone; NA, not available; OS, overall survival; PFS, progression-free survival; PN, peripheral neuropathy; PR, partial response; TTP, time to progression; VMP, bortezomib, melphalan, and prednisone; VMPT, bortezomib, melphalan, prednisone, and thalidomide; VTP, bortezomib, thalidomide, and prednisone.